Drug Profile
Enzalutamide companion diagnostic - Astellas Pharma/ Medivation/ NanoString Technologies
Latest Information Update: 25 Apr 2018
Price :
$50
*
At a glance
- Originator Astellas Pharma; Medivation; NanoString Technologies
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Triple negative breast cancer